Intravesical gemcitabine as bladder-preserving treatment for BCG unresponsive non-muscle-invasive bladder cancer. Results from a single-arm, open-label study.

Rodolfo HurlePaolo CasaleEmanuela MorenghiAlberto SaitaNicolòmaria BuffiGiovanni LughezzaniPiergiuseppe ColomboRoberto ContieriNicola FregoGiorgio GuazzoniMassimo Lazzeri

Published in: BJUI compass (2020)

Patients who presented an unresponsive-BCG recurrent NMIBC and unwilling to receive a RC, could benefit from intravesical gemcitabine as salvage organ-sparing treatment.

Keyphrases

muscle invasive bladder cancer
open label
clinical trial
spinal cord injury
randomized controlled trial
combination therapy
urinary tract
radiation therapy
replacement therapy
minimally invasive